Biohaven Ltd. (BHVN)
NYSE NYSE Primary 
Overlooked Stock: BHVN
Biohaven (BHVN) shares surged after the company's troriluzole drug showed significant slowed progression of spinocerebellar ataxia, a rare neurological disease. George Tsilis shares how the promising results can mark the beginning of a long road to success for Biohaven.
Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug
Biohaven (BHVN) shares soared 15% Monday after the biotech firm announced positive results from a study of its experimental treatment for a rare neurological condition.
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise
Monday, Biohaven Ltd. BHVN released topline results from pivotal Study BHV4157-206-RWE demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after three years of treatment.
Biohaven's stock surges as treatment slows progress of neurological disorder
Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed progress of the condition in a clinical trial.
Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease
Biohaven stock jumped Monday after the company's experimental drug slowed progression in a rare disease with no approved treatments.
Biohaven's genetic disease drug meets main trial goal
Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly affects the brain, the company said on Monday.
The 3 Smartest Healthcare Stocks to Buy With $1K Right Now
Healthcare stocks to buy have been off to the races recently — especially the ones in the weight-loss drug market. Indeed, the market is huge and could entail considerable growth for many years into the future.
